Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD4547 + docetaxel
- Development stage
- Unknown
- Lead developer
- Abbisko Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
AZD4547 + docetaxel is a combination therapy investigated for the treatment of recurrent FGFR1-amplified squamous non-small cell lung cancer (NSCLC). AZD4547 is an orally bioavailable, potent, and selective small molecule inhibitor of the fibroblast growth factor receptors 1, 2, and 3 (FGFR1/2/3). Docetaxel is a taxane-based chemotherapy agent that promotes the assembly of tubulin into stable microtubules and inhibits their disassembly, leading to cell cycle arrest in the G2/M phase and subsequent apoptosis. This combination was evaluated in a Phase I/II clinical trial (NCT01795716) sponsored by the ECOG-ACRIN Cancer Research Group to determine if the dual inhibition of FGFR signaling and mitotic progression could improve outcomes in patients with FGFR-driven squamous NSCLC. Clinical results for this combination in FGFR1-amplified squamous NSCLC have generally shown modest efficacy.
- Brand names
- Taxotere
- Other names
- AZD4547 and docetaxelAZD-4547 and docetaxelAZD 4547 and docetaxelAZD4547 plus docetaxelAZD-4547 plus docetaxelAZD 4547 plus docetaxel
02
Targets
FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AZD4547 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD4547 + docetaxel.